A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
1,035 participants
Dec 15, 2025
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered SC
Administered SC
Locations(159)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07282600